[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Hüser et al., 2018 - Google Patents

Effects of isoflavones on breast tissue and the thyroid hormone system in humans: a comprehensive safety evaluation

Hüser et al., 2018

View HTML
Document ID
3738608328838947796
Author
Hüser S
Guth S
Joost H
Soukup S
Köhrle J
Kreienbrock L
Diel P
Lachenmeier D
Eisenbrand G
Vollmer G
Nöthlings U
Marko D
Mally A
Grune T
Lehmann L
Steinberg P
Kulling S
Publication year
Publication venue
Archives of toxicology

External Links

Snippet

Isoflavones are secondary plant constituents of certain foods and feeds such as soy, linseeds, and red clover. Furthermore, isoflavone-containing preparations are marketed as food supplements and so-called dietary food for special medical purposes to alleviate health …
Continue reading at link.springer.com (HTML) (other versions)

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/574Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57415Specifically defined cancers of breast
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/70Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/704Polygonum, e.g. knotweed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/11Aldehydes

Similar Documents

Publication Publication Date Title
Hüser et al. Effects of isoflavones on breast tissue and the thyroid hormone system in humans: a comprehensive safety evaluation
Zhong et al. Association between dietary isoflavones in soy and legumes and endometrial cancer: a systematic review and meta-analysis
Zhao et al. Dietary isoflavones or isoflavone-rich food intake and breast cancer risk: A meta-analysis of prospective cohort studies
Touillaud et al. Dietary lignan intake and postmenopausal breast cancer risk by estrogen and progesterone receptor status
Duffy et al. Implications of phytoestrogen intake for breast cancer
Hamilton-Reeves et al. Isoflavone-rich soy protein isolate suppresses androgen receptor expression without altering estrogen receptor-β expression or serum hormonal profiles in men at high risk of prostate cancer
Habito et al. Effects of replacing meat with soyabean in the diet on sex hormone concentrations in healthy adult males
EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS) Risk assessment for peri‐and post‐menopausal women taking food supplements containing isolated isoflavones
Pietinen et al. Serum enterolactone and risk of breast cancer: a case-control study in eastern Finland
Holmes et al. Does diet affect breast cancer risk?
Velentzis et al. Do phytoestrogens reduce the risk of breast cancer and breast cancer recurrence? What clinicians need to know
Messina et al. Perspectives on the soy–breast cancer relation
Maskarinec et al. A randomized isoflavone intervention among premenopausal women
Klein et al. Guidance from an NIH workshop on designing, implementing, and reporting clinical studies of soy interventions
Lof et al. Epidemiologic evidence suggests that dietary phytoestrogen intake is associated with reduced risk of breast, endometrial, and prostate cancers
Barlas et al. The estrogenic effects of apigenin, phloretin and myricetin based on uterotrophic assay in immature Wistar albino rats
Budhathoki et al. Soy food and isoflavone intake and endometrial cancer risk: the J apan Public Health Center‐based prospective study
Wang et al. Vitamin K intake and breast cancer incidence and death: results from a prospective cohort study
Valentín-Blasini et al. Urinary phytoestrogen concentrations in the US population (1999–2000)
Woo et al. Sex-specific associations of habitual intake of soy protein and isoflavones with risk of type 2 diabetes
Mishra et al. Phytoestrogens and breast cancer prevention: what is the evidence?
Silva et al. Phyto-oestrogen intake and breast cancer risk in South Asian women in England: findings from a population-based case-control study
Esch et al. Isoflavones: toxicological aspects and efficacy
Mumford et al. Urinary phytoestrogen concentrations are not associated with incident endometriosis in premenopausal women
Tomar et al. Early life and adult exposure to isoflavones and breast cancer risk